VXRT at $0.34 — The Oral Vaccine Innovator Flying Under the Radar

I’ve been following Vaxart (NASDAQ: VXRT) closely, and with the stock currently trading at $0.34, it seems like a hidden gem in the biotech sector.

Why Vaxart?

Vaxart is pioneering oral vaccines—yes, vaccines in pill form. This approach could revolutionize how we think about immunization:
• No needles: Eliminates the discomfort and fear associated with injections.
• No cold storage: Simplifies distribution, especially in regions lacking refrigeration infrastructure.
• Ease of administration: Potentially increases vaccination rates due to convenience.

Their pipeline includes candidates targeting norovirus, seasonal influenza, and HPV, all in various stages of clinical trials. The oral tablet platform they’re developing could be a game-changer in vaccine delivery.

Financial Snapshot:
• Current Price: $0.34
• 52-Week Range: $0.29 – $1.07
• Market Cap: Approximately $130 million
• Analyst Price Target: Around $3.00, suggesting significant upside potential .

The Opportunity:

Biotech stocks are inherently risky, but with high risk comes the potential for high reward. Vaxart’s innovative approach and current valuation present an intriguing opportunity for investors willing to look beyond the mainstream.